• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Lamisil (terbinafine hydrochloride) Solution, 1%

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Lamisil (terbinafine hydrochloride) Solution, 1%

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Lamisil Solution has been approved for the treatment of interdigital-type pedis (athlete's foot), tinea cruris (jock itch) and tinea corporis (ringworm) due to Trichophyton rubrum, Trichophyton mentagrophytes and Epidermophyton floccosum. This product contains the same prescription-strength medication as in the Lamilsi Cream. Both products have been approved for over-the-counter sales for the above indications. Lamisil Solution is also available as prescription-only for the indication of tinea versicolor.

    Lamisil is a one week treatment, whereas most or all other over-the-counter (OTC) treatments for athlete's foot and other fungal infections are four week treatments. The product should be applied once daily for the treatment of tinea corporis and tinea cruris, and twice daily for the treatment of tinea pedis and tinea versicolor.

    The indications:

    • Tinea cruris (jock itch) is a fungal infection of the groin and gluteal cleft
    • Tinea corporis (ringworm) is an infection of the body surface with mold-like fungi called dermatophytes. It often affects children, but can occur in people of all ages.
    • Tinea pedis (Athlete's foot) is a fungal infection of the foot. It affects 1 out of 10 Americans each year and 75% of Americans over their lifetime. A majority of sufferers are males, ages 25-54. Athlete's foot can manifest itself in a variety of ways, ranging from moist, easily rubbed-off skin, to red flaky skin. Symptoms often include itching, blisters and cracking.
    • Pityriasis (tinea) versicolor is a superficial infection caused by a commensal yeast. It is characterized by lesions, scaling and discoloration of the skin. Tinea versicolor affects mostly young adults, but can affect a person in any age group.

    All of these fungal conditions are contagious. Good hygiene, keeping skin dry, and protecting minor skin injuries can all help prevent the spread of these fungal infections.

    Other products with the Lamisil name:

    • Lamisil Tablets prescription oral medication for the treatment of fungal nail infection (onychomycosis)
    • Lamisil Cream over-the-counter cream medication for the treatment of athlete's foot, jock itch, and ringworm

    Clinical Results

    In clinical studies, the Lamisil Solution treatment was investigated versus placebo, for each of the indications. Results showed that at both the end of the one-week treatment period and at the end of the study (8 weeks), patients treated with Lamisil Solution achieved much better effective treatment and complete cure results than did the patients treated with the placebo.

    Side Effects

    Adverse reactions reported by Lamisil Solution-treated patients during clinical studies:

    • Application site reactions, such as burning or irritation (occurred in 1.3% of patients)
    • Itching (occurred in 1.1% of patients)
    • Skin exfoliation (occurred in 1.0% or patients)
    • Erythematous rash (occurred in 0.9% of patients)

    0.2% or the 898 patients participating in clinical trials discontinued therapy due to adverse reactions.

    Lamisil Solution is not for ophthalmic, oral, or intravaginal use.

    Mechanism of Action

    Terbinafine hydrochloride is a synthetic allylamine derivative. Terbinafine hydrochloride is hypothesized to act by inhibiting the epoxidation of squalene, thus blocking the biosynthesis of ergosterol, an essential component of fungal cell membranes. The allylamine derivatives, like the benzylamines, act at an earlier step in the ergosterol biosynthesis pathway than the azole class of antifungal drugs. Depending on the concentration of the drug and the fungal species tested in vitro, terbinafine hydrochloride may be fungicidal. However, the clinical significance of in vitro data is unknown. (From FDA Label)

    Additional Information

    Visit the Novartis Pharmaceuticals Corporation web site to learn more about Lamisil Solution and about other products, research, and services provided by the company that developed this drug.

    To search the internet for dermatology-related topics, visit www.dermguide.com, an internet search engine devoted to dermatological issues.

    For more information about current events in dermatology, case studies in dermatology, interactive emailing with experts in dermatology, etc., visit www.skindex.com.

    Approval Date: 2000-03-01
    Company Name: Novartis
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • TechInnovation-360x240.png

      Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

    • AskTheExperts-360x240.png

      Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing